Gandeeva Therapeutics Inc. has divulged serine/threonine-protein kinase B-raf (BRAF)/MAP2K1 (MEK1) interaction stabilizers reported to be useful for the treatment of brain metastasis.
MD Biopharm Co. Ltd. has identified compounds acting as mitogen-activated protein kinase kinase kinase 11 (MAP3K11; MLK3) and kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer, viral infection, Parkinson’s disease, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH) and tuberculosis.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has synthesized compounds acting as tyrosine-protein kinase receptor UFO (AXL) inhibitors reported to be useful for the treatment of cancer.
ENPP1 contributes to establishing an immunosuppressive tumor microenvironment by blocking the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling, which is critical in antitumor immunity. The inhibition of ENPP1 is an emerging strategy under exploration for cancer immunotherapy.
The next-generation farnesyl transferase inhibitor KO-2806 is currently in phase I clinical development at Kura Oncology Inc. for the treatment of patients with solid tumors, including non-small-cell lung cancer (NSCLC) and colorectal cancer (CRC).
WDR45 is located on the X chromosome. Its pathogenic variants are associated with various neurodegenerative disorders that are predominantly reported in females and present a wide range of clinical phenotypes, from early-onset developmental delay to neurodegeneration and multiple epileptic syndromes.
Trex Bio Inc. has closed an oversubscribed $84 million series B financing round to support development of its pipeline of novel therapies that modulate the immune system to restore human tissue immune homeostasis.
RSS
